NCT06088264View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions
Healthy Male Participants
Interventions
DRUG

BMS-986322

Specified dose on specified days.

Trial Locations (1)

53704

Fortrea Clinical Research Unit, Madison

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY